Home  »  Industry   »  Atai Life Sciences N.V. (ATAI) Is Down -28.20% in ...

Atai Life Sciences N.V. (ATAI) Is Down -28.20% in 2023 With Lots of Room to Run

Atai Life Sciences N.V. (NASDAQ: ATAI) is -28.20% lower on its value in year-to-date trading and has touched a low of $1.45 and a high of $6.32 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ATAI stock was last observed hovering at around $1.89 in the last trading session, with the day’s gains setting it 0.02% off its average median price target of $11.00 for the next 12 months. It is also 90.9% off the consensus price target high of $21.00 offered by 14 analysts, but current levels are 62.55% higher than the price target low of $5.10 for the same period.

Currently trading at $1.91, the stock is -13.08% and -29.93% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.55 million and changing 1.06% at the moment leaves the stock -46.95% off its SMA200. ATAI registered -63.69% loss for a year compared to 6-month loss of -49.47%.

5 Undervalued Stocks For 2023

Approximately 544 miles north of Las Vegas lies what's been dubbed "the biggest lithium deposit in the US." One tiny company stands to be the biggest beneficiary because lithium "faces a long-term supply shortage," according to Barron's. This company, however, is sitting on a goldmine opportunity as it plans to produce 30,000 tonnes per annum over the next 3.5 years from this single deposit. Supplying the electric vehicle boom and potentially driving its stock price off the charts. But this is just one of the opportunities we have researched in our free report. The other four companies have just as much potential.

Click here to download your Free Copy…

Sponsored

The stock witnessed a -39.56% gain in the last 1 month and extending the period to 3 months gives it a -33.22%, and is -1.55% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.85% over the week and 9.95% over the month.

Atai Life Sciences N.V. (ATAI) has around 81 employees, a market worth around $325.20M and $0.40M in sales. Distance from 52-week low is 31.72% and -69.78% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.00%).

Atai Life Sciences N.V. (ATAI) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Atai Life Sciences N.V. (ATAI) is a “Buy”. 14 analysts offering their recommendations for the stock have an average rating of 1.90, where 1 rate it as a Hold and 0 think it is a “Overweight”. 13 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Atai Life Sciences N.V. is expected to release its quarterly report on 05/15/2023.The EPS is expected to shrink by -9.00% this year.

Atai Life Sciences N.V. (ATAI) Top Institutional Holders

The shares outstanding are 156.61M, and float is at 150.49M with Short Float at 3.90%.

Atai Life Sciences N.V. (ATAI) Insider Activity

The most recent transaction is an insider purchase by Apeiron Investment Group Ltd.,the company’s10% Owner. SEC filings show that Apeiron Investment Group Ltd. bought 21,900 shares of the company’s common stock on Apr 29 at a price of $4.47 per share for a total of $97801.0. Following the purchase, the insider now owns 1.8 million shares.

Atai Life Sciences N.V. disclosed in a document filed with the SEC on Apr 28 that Apeiron Investment Group Ltd. (10% Owner) bought a total of 34,700 shares of the company’s common stock. The trade occurred on Apr 28 and was made at $4.46 per share for $0.15 million. Following the transaction, the insider now directly holds 1.78 million shares of the ATAI stock.

Still, SEC filings show that on Apr 27, Apeiron Investment Group Ltd. (10% Owner) acquired 19,803 shares at an average price of $4.64 for $91939.0. The insider now directly holds 1,742,702 shares of Atai Life Sciences N.V. (ATAI).

Atai Life Sciences N.V. (ATAI): Who are the competitors?

The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 2.09% up over the past 12 months and Novan Inc. (NOVN) that is -56.27% lower over the same period. Biogen Inc. (BIIB) is 32.36% up on the 1-year trading charts.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts